Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer

OHSU Knight Cancer Institute66 enrolled

Overview

A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. So, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Prostate Cancer

Interventions

Magnetic Resonance Spectroscopy Imaging with rectal probePROCEDURE

Eligibility

Sex: MALEMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Prostate cancer diagnosis prior to treatment * Age 21 years or older * Signed informed subject consent * Prostatectomy as planned prostate cancer treatment Exclusion Criteria: * Men who do not choose prostatectomy * Men who have undergone any neoadjuvant therapy * Men who have cardiac pacemakers or other implanted electronic devices * Men who have any surgically implanted metal * Men who have had any surgical procedure that precludes placement of endorectal probe * Indication of dementia or memory issues listed on problem list * Men who indicate exposure to ocular metal fragments; confirmed by positive ocular x-ray * Men who are taking newly-prescribed (within 6 months of enrollment) lipid control medications

Outcomes

Primary Outcomes

Number of participants with increased intraprostatic lipid concentration

Determine the correlation between the amount of intraprostatic lipid using 1H (proton) magnetic resonance spectroscopic imaging (MRSI) with an endorectal coil obtained prior to prostatectomy with fatty acid synthase protein expression measured in benign and cancer tissue from prostatectomy samples.

Time frame: Up to 3 years

Secondary Outcomes

Number of participants with increased tumor aggressiveness

Identify the association between fatty acid synthase protein expression in prostatectomy samples, intraprostatic lipid as measured by 1H MRSI, and prostate tumor aggressiveness.